Ithaca, N.Y. — August 17, 2010 — Rheonix, Inc. today announced that the National Institutes of Health has added a $233,044 supplement to its previously awarded Point-of-Care Partnership grant. The POC Partnership grant is funded to develop a fully automated molecular diagnostic for the detection of multiple sexually transmitted infections (STI). The supplement, awarded under the American Recovery and Reinvestment Act (ARRA) of 2009, was added to expand the scope… Read More »
Ithaca, NY — July 27, 2010 — Rheonix, Inc. today announced positive results from three separate studies of the Rheonix CARD™ (Chemistry And Reagent Device) system presented in poster sessions at the American Association for Clinical Chemistry (AACC) Annual Meeting held in Anaheim, CA, July 25-29, 2010. The data presented demonstrate the utility of the Rheonix CARD™ system as a powerful, analytic platform for the life science industry. In studies… Read More »
Ithaca, NY — April 21, 2010 — Rheonix, Inc. today announced the completion of a $12.6 million Series A financing to continue development of the Rheonix CARD™ (Chemistry And Reagent Device) system. This powerful, analytic platform for the lifescience industry vertically integrates all the functions of traditional molecular diagnostic instrumentation into a single system to achieve unprecedented raw sample preparation, molecular amplification and multiplex analysis. The Rheonix CARD system provides… Read More »
Ithaca, N.Y. — April 16, 2010 — Rheonix, Inc. today announced that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), continues to support its Point-of-Care Partnership with Rheonix for a second year. As part of the grant, Rheonix will receive an additional $396,775 award to optimize its CARD™ (Chemistry And Reagent Device) diagnostic platform for simultaneous, multiplex, point-ofcare detection of the… Read More »
Ithaca, N.Y. — Tuesday, January 19, 2010 — Rheonix, Inc. today announced the receipt of a National Science Foundation (NSF) Small Business Innovation Research Phase IB grant. The award decision recognizes the substantial progress made by Rheonix during the NSF-funded Phase I program to develop a rapid biosensor to monitor recreational water safety and the Company’s ability to attract significant funding from the New York State Energy Research and Development… Read More »
Ithaca, NY — Tuesday, January 12, 2010 — Rheonix, Inc. announced that on October 27, 2009 the U. S. Patent and Trademark Office issued Patent Number 7,608,160, Laminated Microfluidic Structures and Method for Making, the first grant of U. S. patent rights for the Company’s microfluidic lamination technology. A patent claiming the same technology has also issued in China.
“These patents recognize the unique contribution that inventors Dr. Peng Zhou and… Read More »
Ithaca, N.Y. — June 8, 2009 — Rheonix, Inc. today announced the receipt of a $99,928 Small Business Innovation Research Phase I grant from the National Science Foundation (NSF) to develop a rapid test to monitor recreational water for safety. Upon successful completion of the six month Phase I program, Rheonix will be eligible to compete for additional Phase II funding to finalize the prototype test developed during the Phase… Read More »
Ithaca, N.Y. — May 13, 2009 — Rheonix, Inc. today announced the receipt of a $1.67 Million award from the National Institutes of Health (NIH) as the Company and NIH establish a partnership for the development of point-of-care (POC) technologies for underserved and nontraditional health care settings such as rural and urban community public heath-care clinics and temporary medical facilities established in response to natural or human-made disasters.
“This significant financial… Read More »
Ithaca, N.Y. — March 31, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, will receive a $100,000 Phase I grant from the National Institutes of Allergy and Infectious Diseases (NIAID) to develop a biosensor for the rapid detection of the causative agent of tuberculosis (TB) in human clinical specimens. The grant will come through NIAID’s Small Business Innovative Research (SBIR)… Read More »
Ithaca, N.Y. — March 17, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, announced an additional $120,000 award from the U.S. Environmental Protection Agency (EPA) to further commercialize its biosensor technology for the rapid detection of Cryptosporidium parvum in drinking water.
Cryptosporidium parvum can cause serious illness in infants and the elderly. The largest outbreak of the infection occurred in Milwaukee… Read More »